| Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease CD Reiter, X Wang, JE Tanus-Santos, N Hogg, RO Cannon, ... Nature medicine 8 (12), 1383-1389, 2002 | 1371 | 2002 |
| A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs F Barbosa Jr, JE Tanus-Santos, RF Gerlach, PJ Parsons Environmental health perspectives 113 (12), 1669-1674, 2005 | 834 | 2005 |
| Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants JE Tanus-Santos, M Desai, DA Flockhart Pharmacogenetics and Genomics 11 (8), 719-725, 2001 | 347 | 2001 |
| Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre … RD Lopes, RHM Furtado, AVS Macedo, B Bronhara, LP Damiani, ... The Lancet 397 (10291), 2253-2263, 2021 | 346 | 2021 |
| Circulating interleukin‐6 and high‐sensitivity C‐reactive protein decrease after periodontal therapy in otherwise healthy subjects AM Marcaccini, CA Meschiari, CA Sorgi, MCP Saraiva, AM de Souza, ... Journal of periodontology 80 (4), 594-602, 2009 | 212 | 2009 |
| Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia VC Sandrim, ACT Palei, IF Metzger, VA Gomes, RC Cavalli, ... Hypertension 52 (2), 402-407, 2008 | 208 | 2008 |
| Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats MM Castro, E Rizzi, L Figueiredo-Lopes, K Fernandes, LM Bendhack, ... Atherosclerosis 198 (2), 320-331, 2008 | 201 | 2008 |
| Gingival crevicular fluid levels of MMP‐8, MMP‐9, TIMP‐2, and MPO decrease after periodontal therapy AM Marcaccini, CA Meschiari, LR Zuardi, TS De Sousa, M Taba Jr, ... Journal of clinical periodontology 37 (2), 180-190, 2010 | 196 | 2010 |
| Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms AS Marroni, IF Metzger, DC Souza-Costa, S Nagassaki, VC Sandrim, ... Nitric Oxide 12 (3), 177-182, 2005 | 180 | 2005 |
| Biological activity of nitric oxide in the plasmatic compartment X Wang, JE Tanus-Santos, CD Reiter, A Dejam, S Shiva, RD Smith, ... Proceedings of the National Academy of Sciences 101 (31), 11477-11482, 2004 | 178 | 2004 |
| Implications of cytochrome P450 interactions when prescribing medication for hypertension DA Flockhart, JE Tanus-Santos Archives of internal medicine 162 (4), 405-412, 2002 | 170 | 2002 |
| Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension MM Castro, E Rizzi, GJ Rodrigues, CS Ceron, LM Bendhack, RF Gerlach, ... Free Radical Biology and Medicine 46 (9), 1298-1307, 2009 | 164 | 2009 |
| Sodium nitrite downregulates vascular NADPH oxidase and exerts antihypertensive effects in hypertension MF Montenegro, JH Amaral, LC Pinheiro, EK Sakamoto, GC Ferreira, ... Free Radical Biology and Medicine 51 (1), 144-152, 2011 | 145 | 2011 |
| Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms GH Oliveira-Paula, R Lacchini, JE Tanus-Santos Gene 575 (2), 584-599, 2016 | 143 | 2016 |
| Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol JE Tanus-Santos, M Desai, LR Deak, JC Pezzullo, DR Abernethy, ... Pharmacogenetics and Genomics 12 (5), 407-413, 2002 | 143 | 2002 |
| Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes IF Metzger, JTC Sertório, JE Tanus-Santos Free Radical Biology and Medicine 43 (6), 987-992, 2007 | 138 | 2007 |
| Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma RF Gerlach, C Demacq, K Jung, JE Tanus-Santos Clinical biochemistry 40 (1-2), 119-123, 2007 | 137 | 2007 |
| Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and … ACT Palei, VC Sandrim, RC Cavalli, JE Tanus-Santos Clinical biochemistry 41 (10-11), 875-880, 2008 | 136 | 2008 |
| Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities RF Gerlach, JA Uzuelli, CD Souza-Tarla, JE Tanus-Santos Analytical biochemistry 344 (1), 147-149, 2005 | 135 | 2005 |
| Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities CD Souza-Tarla, JA Uzuelli, AA Machado, RF Gerlach, JE Tanus-Santos Clinical biochemistry 38 (5), 410-414, 2005 | 131 | 2005 |
Ingrid Ferreira MetzgerDivision of Clinical Pharmacology - Indiana University School of MedicineVerified email at iupui.edu
